Clinical Trial Update: Study of HuMax-CD20, a New Drug to Treat Early Stage Non-Hodgkin´s Follicular Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

The Phase 1/2 clinical trial evaluating HuMax-CD20 for early-stage follicular lymphoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• HuMax-CD20 (ofatumumab)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Lymphoma, Follicular | Phase 1, Phase 2 | Status: WITHDRAWN